432 results on '"Kourelis, Taxiarchis V."'
Search Results
2. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
3. Gastrointestinal amyloidosis: an often unexpected finding with systemic implications
4. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
5. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
6. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases
7. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
8. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
9. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center
10. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update
11. IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis
12. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma
13. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy
14. Aging-associated immune system changes in multiple myeloma: The dark side of the moon.
15. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
16. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
17. A Proteomic Atlas of Cardiac Amyloid Plaques
18. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients
19. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
20. Utility of serum free light chain ratio in response definition in patients with multiple myeloma
21. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
22. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
23. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
24. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
25. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
26. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved
27. Impact of acquired del(17p) in multiple myeloma
28. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
29. Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis
30. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing
31. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
32. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
33. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma
34. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
35. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
36. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation
37. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
38. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis
39. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio
40. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
41. Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
42. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience
43. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
44. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
45. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
46. Venetoclax for the treatment of translocation (11;14) AL amyloidosis
47. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis
48. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
49. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
50. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.